1Hu TS,Liu Q,Zhang MF.Association with HLA-DRB1 * 0405,-DQA1*0301, -DQB1*0401 in patients with Vogt-Koyanagi-Harada syndrome[].Investigative Ophthalmology.1999
2Sugiura S.Vogt-Koyanagi-Harada disease[].Japanese Journal of Ophthalmology.1978
3Synder DA,Tessler HA.Vogt-Koyanagi-Harada Syndrome[].American Journal of Ophthalmology.1980
4Inomata H,Sakamoto T.Immunohistochemical studies of VogatKoyanagi-Harada disease with sunset sky fundus[].Current Eye Research.1990
5Shindo Y,Ohno S,Usui M,et al.Immunogenetic study of sympathetic ophthalmia[].Tissue Antigens.1997
6Woods AC.Sympathetic ophthalmia[].American Journal of Ophthalmology.1936
7Rao NA,Foster DJ,Auburger JJ.The uvea: intraocular inflammation and neoplasms[]..1992
7Mitchell P. Asystematic review of the efficacy and safety outcomes of anti- VEGF agents used for treating neovascular age- related macular degenera- tion:comparison of ranibizumab and bevacizumab. Curr Med Res Opin, 2011,27:1465-1475.
8Hurwitz H, Fehrenbacher L, Novotny W, et al. Bevacizumab plusirinotee- an,fluorouracil and leucovofin for metastatic colorectaleancer. N Engl J Med ,2004,350:2335-2342.
